Biological markers to predict response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC): Ready for prime time?

被引：0
|
作者：
Pino, M. S. [1 ]
Fabi, A. [1 ]
Tedeschi, M. [1 ]
Mottolese, M. [1 ]
Papaldo, P. [1 ]
Vici, P. [1 ]
Ferretti, G. [1 ]
Nistico, C. [1 ]
Russillo, M. [1 ]
Cuppone, F. [1 ]
Di Benedetto, A. [1 ]
Botti, C. [1 ]
Giannarelli, D. [1 ]
Cognetti, F. [1 ]
机构：
[1] Regina Elena Inst Canc Res, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11073
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Additional metabolic effects at the neoadjuvant chemotherapy (NCT) of locally advanced breast cancer (LABC).
    Abramova, Natalya A.
    Vladimirova, Liubov Yu
    Shikhliarova, Alla I.
    Storozhakova, Anna E.
    Kova, Valeriya S. Myag
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Does neoadjuvant chemotherapy (NAC) alter biological markers in locally advanced breast cancer (LABC)?
    Seno, R
    Sparano, JA
    Fineberg, S
    [J]. LABORATORY INVESTIGATION, 1996, 74 (01) : 121 - 121
  • [3] The usefulness of FDG-PET in predicting response to neoadjuvant chemotherapy (NCT) in patients with locally-advanced breast cancer (LABC)
    Schneider-Kolsky, M. E.
    Midolo, P.
    Hart, S.
    Stuckey, J.
    Baldey, A.
    Fox, J.
    Rogers, P. A. W.
    Strickland, A.
    Susil, B.
    Ganju, V.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 135 - 135
  • [4] IMMUNOHISTOCHEMICAL PREDICTORS OF PATHOLOGICAL RESPONSE IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER (LABC) UNDERGOING PACLITAXEL-BASED NEOADJUVANT CHEMOTHERAPY (NCT)
    De Rosa, G.
    Montemurro, F.
    Redana, S.
    Ponzone, R.
    Martincich, L.
    Gatti, M.
    Sarotto, I.
    Biglia, N.
    Risio, M.
    Sismondi, P.
    Aglietta, M.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 13 - 14
  • [5] Neoadjuvant chemotherapy with Vinorelbine and Epirubicin in locally advanced breast cancer (LABC).
    Puerto, VL
    Cardenas, J
    Lara, F
    Goana, R
    Silva, A
    Barroso, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 299 - 299
  • [6] FDG PET can be useful to predict survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer (LABC)
    Rousseau, C.
    Campion, L.
    Pallardy, A.
    Campone, M.
    Testard, A.
    Ferrer, L.
    Bridji, B.
    Kraeber-Bodere, F.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S246 - S247
  • [7] Identification of predictive markers for tumour response to neo-adjuvant chemotherapy (NCT) treatment for locally-advanced breast cancer (LABC)
    Ganju, V.
    Strickland, A.
    Hart, S.
    Fox, J.
    Stuckey, J.
    Baldey, A.
    Schneider-Kolsky, M.
    Susil, B.
    Wu, D.
    Rogers, P.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 104 - 104
  • [8] Biological predictors of response to neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Yaziji, H
    Newman, I
    Kuerer, HM
    Singletary, E
    Hortobagyi, G
    Atkinson, N
    Sneige, N
    [J]. LABORATORY INVESTIGATION, 1999, 79 (01) : 34A - 34A
  • [9] Docetaxel and epirubicin as neoadjuvant chemotherapy (CT) in locally advanced breast cancer (LABC).
    Alkhatib, F
    Alawadi, S
    Grohn, P
    Motawy, M
    Fayaz, S
    Patel, J
    Attia, N
    Trad, D
    Delvadia, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 21 - 22
  • [10] Breast magnetic resonance imaging (MRI): a useful tool for therapeutic decision in patients treated for locally Advanced breast cancer (LABC) by neoadjuvant chemotherapy (NCT).
    Gligorov, J
    Chopier, J
    Benchimol, Y
    Barranger, E
    Antoine, M
    Lotz, JP
    Uzan, S
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 238 - 238
12345